Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191467 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL193562 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| Hydrochloric Acid SCHEMBL27589925 | 0.98 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL28283143 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL204822 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL28462179 | 0.85 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL28462181 | 0.85 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1LMNAGAAHPGD | |
| SCHEMBL192729 | 0.84 | CA2 (0.40) | ALDH1A1CA2CA1CTSS | |
| SCHEMBL3449046 | 0.84 | CA2 (0.40) | ALDH1A1CA2CA1CTSS | |
| SCHEMBL16499390 | 0.84 | CA2 (0.40) | ALDH1A1CA2CA1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1737 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071449-A | Substituted biphenyl compounds and application thereof in synthesis of cola pyrroside | 北京凯因格领生物技术有限公司 | 2026-05-22 | — | — | CN | claimed |
| CN-117865973-A | Synthesis method of S-S type aryl halogen compound | 常州寅盛药业有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-113072615-B | Preparation method of vipatavir intermediate | 上海法默生物科技有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-114805306-A | Production process of Yimitatawei | 宜昌东阳光长江药业股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114685316-A | MOC-L-valine synthesis process | 常州吉恩药业有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2022-05-31 | — | — | US | claimed |
| CN-113072615-A | Preparation method of vipatavir intermediate | 上海法默生物科技有限公司 | 2021-07-06 | — | — | CN | claimed |
| WO-2021080458-A1 | PANGENOTYPIC INHIBITOR OF HEPATITIS C VIRUS NS5A PROTEIN | ИВАЩЕНКО, Александр Васильевич | 2021-04-29 | — | — | WO | claimed |
| CN-111825659-A | Impurity hydrochloride of dalatavir hydrochloride, preparation method and application thereof | 扬子江药业集团有限公司 | 2020-10-27 | — | — | CN | claimed |
| CN-111334265-A | Clay mineral nano hydrogel plugging agent and water-based drilling fluid | 西南石油大学 | 2020-06-26 | — | — | CN | claimed |
| CN-105294828-A | Preparation method of Ombitasvir | SUZHOU MIRACPHARMA TECHNOLOGY CO LTD | 2016-02-03 | — | — | CN | claimed |
| US-9056860-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-06-16 | — | — | US | claimed |
| CN-104520293-A | Synthesis of Antiviral Compounds | GILEAD PHARMASSET LLC | 2015-04-15 | — | — | CN | claimed |
| EP-2855454-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | Gilead Pharmasset LLC (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2013184702-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | claimed |
| US-20130324740-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | claimed |
| CN-102883718-A | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMA | 2013-01-16 | — | — | CN | claimed |
| EP-2515902-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2012-10-31 | — | — | EP | claimed |
| WO-2011079327-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | WO | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344858-B2 | Micro-electrolysis reactor for ultra fast, oxidant free, C—C coupling reaction and synthesis of daclatasvir analogs thereof | CYCS, COASY, CAT | SMN1; SMN2 4798/4885ALDH1A1 532/4885LMNA 3358/4885 |
| US-20130324740-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | SMN1; SMN2 2594/4885ALDH1A1 2746/4885LMNA 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.